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Original Studies
Background: Diverse scores on high-risk Kawasaki disease (KD) patients 
have proven a good prognostic validity in the Japanese population. How-
ever, data on non-Japanese have been inconclusive. Do the Kobayashi, 
Egami and Sano scores or application of up-to-date statistical methods 
(Random Forest) predict response to standard intravenous immunoglobulin 
(IVIG) therapy and the risk of persistent coronary artery aneurysm (CAA) 
in patients with KD in a mainly Caucasian population in Germany?
Methods: Data on 442 children (German population-based survey, 2013 
and 2014) were used to assess the prognostic validity of the Kobayashi, 
Egami and Sano scores for being refractory to IVIG treatment and for pre-
dicting the risk of persistent CAA. Additionally, an up-to-date statistical 
approach (Random Forest) was applied to identify a potentially more valid 
score.
Results: A total of 301 children were eligible for assessment of their 
response to IVIG treatment. Among those, 177 children were followed-up 
for 1 year to identify persistent CAA. Although all scores were significantly 
associated with being refractory to IVIG (relative risk range between 2.32 
and 3.73), the prognostic properties were low (likelihood ratio positive: 
1.83–4.57; sensitivity in the range of 0.28–0.53). None of the scores was a 
significant predictor of CAA 1 year after acute illness. Application of sta-
tistical analysis such as Random Forest did not yield a more valid score.
Conclusions: None of the available scores appears to be appropriate for 
identifying high-risk Caucasian children with KD who might need intensi-
fied therapy.
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(Pediatr Infect Dis J 2018;37:850–855)
Kawasaki disease (KD) is an acute febrile vasculitis of unknown etiology. The process of vascular inflammation is especially 
evident at the coronary artery level. This accounts for persistent 
coronary artery aneurysms (CAAs) with a high impact on long-
term morbidity and mortality. Most, but not all affected children 
respond to a first intravenous immunoglobulin (IVIG) treatment. 
Response to IVIG treatment has been found to be a negative predic-
tor for incident and persistent CAA.1 Currently, prediction of failure 
to respond to IVIG treatment is considered crucial for the purpose 
of identifying children who may need early supplementary immu-
nosuppressive therapy. Although additional use of corticosteroids 
may have a positive impact on the course of fever and inflamma-
tion,2,3 a beneficial effect on the aneurysm rate was only observed 
in high-risk Japanese children4–6 identified by the Kobayashi score.
The Kobayashi score and other scores (Egami,7 Sano8) have 
been evaluated for prediction of being refractory to initial IVIG 
treatment in Japanese children. Data on the ability of these scores 
to validly predict response to standard IVIG therapy outside Japan 
has been limited. Additionally, the association between response to 
therapy and risk of developing CAA has been ambiguous.9,10 The 
latest scientific statement from the American Heart Association 
(AHA) from the year 2017 only recommended the adjunctive use of 
corticosteroids when high-risk patients can be clearly identified.11
From 2013 to 2014, a German study collected active sur-
veillance data on 442 children with KD. The study addressed the 
following questions:
In a primarily Caucasian population in Germany, how well 
do the Kobayashi and other scores predict first response to standard 
IVIG therapy and the risk of persistent CAA in patients with KD? 
Does the application of up-to-date statistical methods such as Ran-
dom Forest allow for the determination of a highly predictive score 
in this population?
PATIENTS AND METHODS
Nationwide active surveillance through the hospital-based Ger-
man Pediatric Surveillance Unit (ESPED) was used to recruit eligible 
KD patients. For the years 2011 and 2012, the incidence of KD in 
Germany (children <5 years) recently has been determined to be 7.2 
in 100,000.12 Between January 1, 2013, and December 31, 2014, 442, 
presumed cases of KD were reported in Germany. Pseudonymous iden-
tifiers were employed in these ESPED reports. Reporting physicians 
were sent a standardized questionnaire explicitly requesting all param-
eters required for analysis. For numeric parameters, such as laboratory 
values, the reporting physicians were asked to document the measured 
values along with their respective units. For categorical parameters, 
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correspondents were provided the option of checking either “yes” or 
“no.” Additionally, through a written informed consent request sent by 
the treating physician, parents were asked whether they would agree 
to the disclosure of their children’s identities for the study. In the cases 
where consent was provided, we validated the questionnaire data via 
discharge letters, recorded laboratory values and echocardiographic 
findings. Due to data protection regulations, follow-up only was pos-
sible in cases where parents had provided written consent. The ESPED 
reports were used to assess the diagnostic validity of Kobayashi and 
other scores in their ability to predict response to initial IVIG treatment. 
Due to the need for informed consent, long-term risk for persistent 
CAA was evaluated only in children with known identities. Exclusion 
criteria were: failure to comply with the clinical case definition; IVIG-
untreated patients; steroid administration concurrent with the first IVIG 
therapy (±2 days); and, in cases where neither “yes” nor “no” was ticked 
on the questionnaire, uncertain steroid exposure. (In the context of the 
study, steroid administration was considered a confounder regarding 
clinical outcome.) Approval for the study was provided by the Ethics 
Committee of the University of Freiburg, in accordance with the ethical 
standards to the Declaration of Helsinki.
DEFINITIONS
Kawasaki Disease
AHA guidelines1 were used to classify complete and incom-
plete KD cases. Complete cases were defined as those with persis-
tent fever for ≥5 days or fever that resolved in <5 days in response 
to IVIG treatment. Additionally, display of at least 4 principal clini-
cal features was required: (1) changes in extremities; (2) polymor-
phous exanthema; (3) bilateral conjunctival inflammation without 
exudate; (4) changes in the lips and oral cavity and (5) cervical 
lymphadenopathy. Incomplete cases included those with fever and 
those showing fewer than 4 clinical features but with detection of 
CAAs. As in other population-based surveillance studies,13 diag-
nosis of CAA was determined based on the clinical judgment of 
the reporting physician. In Germany, 2 criteria for aneurysms are 
applied. The first criteria follow those of the Japanese Ministry of 
Health, which defines aneurysms as either a lumen >3 mm in chil-
dren younger than 5 years, as a diameter 1.5 times the size of the 
surrounding segment, or as a clearly irregular lumen. The second 
criteria are defined as a Z score of >2.5 for one of the coronary 
arteries.14 In accordance with AHA guidelines, cases with fever 
persisting for longer than 36 hours and therefore given a second 
dose of IVIG were defined as “refractory to IVIG.”
Kobayashi Score
The Kobayashi score assigns 2 points for each of the fol-
lowing: (1) sodium ≤133 mmol/L; (2) days of illness before initial 
treatment ≤4; (3) aspartate aminotransferase (AST) ≥100 IU/L 
and (4) neutrophil count ≥80 %. Additionally, the score assigns 
one point for fulfilling the following criteria: (5) C-reactive pro-
tein (CRP) ≥10 mg/dL; (6) age ≤12 months and (7) platelet count 
≤30.0 × 104/mm3. In the literature, different cutoff values have been 
applied for labeling high-risk patients (ie, >3 and >4).
Sano Score
The Sano score labels patients as high risk when at least 1 
of the 2 following criteria apply: (1) CRP ≥7.0 mg/dL; (2) bilirubin 
≥0.9 mg/dL or (3) AST ≥200 IU/L.
Egami Score
The Egami score assigns patients to the high-risk group 
when at least 3 of 6 possible points apply: (1) age ≤6 months 
(1 point); (2) days of illness at initial treatment ≤4 (1 point); (3) 
platelet count ≤30.0 × 104/mm3 (1 point); (4) CRP ≥8 mg/dL (1 
point) and (5) alanine aminotransferase ≥80 IU/L (2 points).
In our main analysis, missing values in one of the required 
laboratory parameters were rated as “absence of the risk factor.” A 
sensitivity analysis used only cases with complete information on 
all risk factors.
STATISTICAL ANALYSIS
Descriptive statistics were performed using the statistical 
software R (R 3.1.0). For all outcomes “refractory to IVIG,” “aneu-
rysm after 4 weeks” and “aneurysm after 1 year,” we assessed the 
risk increase related to high-risk classification in 3 scores (Kob-
ayashi, Egami und Sano). We additionally assessed indicators of 
the prognostic value—that is, sensitivity, specificity, positive and 
negative prognostic value and positive likelihood ratio (LR+). On 
this basis, we calculated 95% confidence interval (CI) for relative 
risk and likelihood risk. In a sensitivity analysis, the respective risk 
ratios and LR+ also were determined for cases that had obtained 
complete information regarding the defining score parameters 
(Table, Supplemental Digital Content 1, http://links.lww.com/INF/
C969). Additional sensitivity analyses were conducted including 
all eligible KD cases (Tables, Supplemental Digital Content 3–5, 
http://links.lww.com/INF/C971; http://links.lww.com/INF/C972; 
http://links.lww.com/INF/C973).
The relative risk for being refractory to IVIG, along with 
that for coronary aneurysms after 4 weeks and after 1 year, was 
assessed in relation to the 3 risk scores (Tables 1 and 2).
To develop a potentially more discriminating score for 
defining high-risk groups in non-Japanese children, our study 
attempted—via univariate analysis—to identify clinical, echo-
cardiographic and laboratory parameters significantly associated 
with being refractory to initial IVIG treatment (Table 3). For 
TABLE 1. CAA After 4 wk (n = 22/175): Numbers at High Risk for CAA After 4 wk 









Risk: High- vs. 
Low-risk Cases 












7 (19) 1.74 (0.77–3.95) 0.32 0.80 0.19 0.89 1.60 (0.81–3.24)
Kobayashi >3
n = 60
11 (18) 1.92 (0.88–4.16) 0.50 0.68 0.18 0.90 1.56 (0.97–2.52)
Sano
n = 18
5 (28) 2.57 (1.08–6.12) 0.23 0.92 0.28 0.89 2.88 (1.06–6.78)
Egami
n = 49
9 (18) 1.78 (0.81–3.90) 0.41 0.74 0.18 0.90 1.58 (0.89–2.76)
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these, we calculated Random Forests,15 a statistical method that 
expands on well-known classification and regression trees.16 clas-
sification and regression trees (CART) uses a given set of covari-
ates and identifies optimal cutoff values to best divide a data set 
into 2 groups relating to a response variable (eg, refractory “yes” 
or “no”). Based on different cutoffs, Random Forests averages 
a large number of classification and regression tree decisions to 
provide an efficient and computationally stable method for detect-
ing the most predictive variables for explaining the respective 
response variable without also providing cutoff values.
RESULTS
Out of 442 presumed KD cases reported, 342 were classified 
as complete and 26 as incomplete according to the AHA guide-
lines (Fig. 1). From the total, 72 children did not meet the required 
clinical definition criteria. Additionally, 2 Japanese children were 
excluded. All 301 patients included in our analysis had had at least 
1 IVIG dose and were labeled as “Kawasaki cases with standard 
therapy.” Follow-up for 1 year was available for 177 of the children. 
Cases with and without follow-up did not differ with respect to 
sociodemographics or to clinical symptoms during the acute phase 
(Table, Supplemental Digital Content 2, http://links.lww.com/INF/
C970). Among the follow-up cases, there was 1 case treated with 
infliximab, methotrexate and anakinra. This child already had had 
giant CAA early in the course of the disease, and this CAA per-
sisted at the 1-year follow-up. In fact, according to all scores when 
treated with IVIG, this child would have been assigned as high risk.
Among the cases, the proportion of boys was 65%. Ethnic 
background was available in 90% of cases and showed a breakdown 
of 95% Caucasian, 3% Asian and 2% black African.
Over half the patients (189 or 63%) were 1 to 4 years old, 
47 (16 %) were refractory to IVIG, 67 (22%) had CAA in the acute 
phase, 22 (13% had CAA after 4 weeks) and 10 (6%) had CAA 
after 1 year. High-risk status was assigned to 21% of the cases 
according to the Kobayashi score >4 (33% Kobayashi score >3), 
9% according to the Sano score and 28% according to the Egami 
score (Table 4).
All scores indicated an increased risk for being refractory (all 
95% CI’s excluded 1: no effect, Table 5). The LR+ of the Sano score 
was 4.67 (95% CI: 2.39–9.19). This indicates a 46% probability of 
being refractory, given that the Sano score is high (post-test probabil-
ity) as compared with the 16% probability of being refractory in the 
entire cohort without the application of any score (pretest probabil-
ity). The respectively predicted post-test probabilities for the Kob-
ayashi score >4 were 31% (>3, 25%) and 27% for the Egami score.
TABLE 2. CAA After 1 yr (n = 10/177): Numbers at High Risk for CAA After 1 yr According 









High- vs.  
Low-risk Cases 












3 (8) 1.62 (0.44–5.97) 0.30 0.80 0.08 0.95 1.50 (0.55–3.98)
Kobayashi >3
n = 60
5 (8) 1.95 (0.59–6.47) 0.50 0.67 0.08 0.96 1.52 (0.79–2.93)
Sano
n = 18
2 (11) 2.21 (0.51–9.61) 0.20 0.90 0.11 0.95 2.00 (0.56–7.85)
Egami
n = 50
4 (8) 1.69 (0.50–5.75) 0.40 0.72 0.08 0.95 1.43 (0.65–3.23)
TABLE 3. Laboratory Values for Refractory and 
Nonrefractory Patients (n = 301)
Laboratory
Refractory: Yes  
(n = 47)
Mean
Refractory: No  
(n = 245)
Mean
P value  
t test
Albumin (g/dL) 2.65 3.04 0.008
AST (U/L) 162.81 94.86 0.049
Total protein (g/dL) 8.18 7.58 0.825
ALT (U/L) 150.10 93.54 0.024
Gamma-GT (U/L) 119.24 82.40 0.156
Bilirubin (mg/L) 8.42 6.10 0.415
CRP (mg/L) 160.88 104.28 <0.0001
Sodium (mmol/L) 132.26 134.18 0.006
Potassium (mmol/L) 3.91 4.23 0.130




Hemoglobin (g/dL) 8.81 10.33 <0.0001
WBC count (count/µL) 23.13 16.77 0.002




ALT indicates alanine aminotransferase; ESR, erythrocyte sedimentation rate; 
WBC, white blood cell count.
FIGURE 1. Flow chart of the study cohort.
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After 4 weeks, only the Sano score indicated an increased 
risk for aneurysm. After 1 year, none of the scores predicted an 
increased risk. Accordingly, the LRs+ for CAA after 4 weeks were 
only significantly increased for the Sano score (Tables 1 and 2). 
Being refractory to IVIG was associated with an increased risk for 
CAA after 4 weeks (Relative Risk = 2.46, 95% CI: 1.17–5.08); 
however, there was no association with an increased risk of having 
an aneurysm after 1 year (RR = 1.33, 95% CI: 0.37–4.68).
As shown in Table 3, several laboratory values and hydrops of 
the gallbladder were significantly associated with being refractory. 
Laboratory values measured on a continuous scale were fed into 
the analysis without prior dichotomization. Therefore, no cutoffs 
for these parameters are provided. The model underlying the Ran-
dom Forest method using hydrops of the gallbladder, albumin, AST, 
alanine aminotransferase, CRP, sodium, erythrocyte sedimentation 
rate, thrombocytes, hemoglobin and white blood cell count is based 
on repetitive CART trees and provides a summary estimate. The 
Random Forest method identified 14 patients as high-risk patients. 
The most discriminating variable was hemoglobin, followed by 
AST and thrombocytes. The respective specificity for the high-risk 
group was 98%, accounting for a high LR+ of 15 (CI: 5.10–31.15). 
Unfortunately, sensitivity achieved was only 30%—that is, however 
not higher than that for the established scores (Table 6).
DISCUSSION
By applying different scores for KD in a primarily Caucasian 
population, we were able to assess and compare their predictive value 
regarding being refractory in relation to standard IVIG and regarding 
risk of mid- or long-term (1 year) CAA. Although high-risk cases 
as assigned by all scores were associated with an increased risk for 
being refractory, the prognostic value of these scores was low as indi-
cated by poor sensitivity and by a small LR+. This was irrespective of 
the cutoff values applied by the Kobayashi score. In terms of predict-
ing CAA, only the Sano Score showed a significantly elevated risk 
and LR+ for CAA after 4 weeks but with poor sensitivity and positive 
predictive value. Although several laboratory values and hydrops of 
the gallbladder were significantly associated with being refractory in 
our mainly Caucasian patient cohort, the Random Forest approach 
unfortunately, did not yield a more valid prognostic score.
We have focused the discussion on the outcome of being refrac-
tory, because the 3 Japanese scores were originally designed to detect 
resistance to IVIG. For a number of studies, reported in the literature, 
we have listed the published study characteristics and prognostic 
indicators in Table 7, Supplemental Digital Content, http://links.lww.
com/INF/C975. Although all studies gave sensitivity and specificity, 
few showed the positive and negative predictive values and none the 
LR+. While the assessed scores appeared to be fairly predictive in 
Japanese children,5–8,17,18 they seemed to be of less clinical relevance 
in non-Japanese Asian KD children.19,20 A study evaluating all 3 scores 
in Korean KD children even yielded somewhat lower sensitivities for 
IVIG nonresponsiveness than our study did (range of 28%–34%). In 
a KD patient cohort from east China, both scores’ sensitivity (Egami 
and Kobayashi) was 57.1% with regard to response to IVIG. In Cau-
casian children, these scores also failed to validly predict high risk in 
KD children (sensitivity through all scores was 26%–58%). A Med-
line search on the phrase “Kawasaki disease and scores and/or IVIG 
resistance” yielded 5 publications that focused primarily on Caucasian 
children. Three publications were from Europe10,21,22 and 2 from the 
United States.9,23 Regarding being refractive to IVIG, an English10 and 
Polish22 study evaluated the Kobayashi score in a monocentric, small 
sample size study; meanwhile, a Catalonian study group assessed the 
TABLE 4. General Patient and Score Defining 
Characteristics of the Included Standard Kawasaki Cases 
(n = 301)
General Characteristics n (%)
Gender: boys 196 (65)
Age (yr)
  <1 52 (17)
  1–4 189 (63)
  ≥5 60 (20)
Refractory to IVIG: yes 47 (16)
CAA
  In acute phase 67 (22)
  After 4 wk* 22 (13)
  After 1 yr† 10 (6)
Kobayashi score >4/>3 64 (21)/99 (33)
  Days of illness at initial treatment ≤4 82 (27)
  Age ≤1 yr 52 (17)
  Sodium ≤133 mmol/L 103 (34)
  AST ≥100 IU/L 62 (21)
  Neutrophils ≥80% 65 (22)
  CRP ≥10 mg/dL 141 (47)
  Thrombocytes ≤300 × 109/L 35 (12)
Sano score >1 28 (9)
  CRP ≥7 mg/dL 185 (62)
  Bilirubin ≥0.9 mg/dL 20 (7)
  AST ≥200 IU/L 27 (9)
Egami score >2 85 (28)
  Age ≤6 mo 24 (8)
  Days of illness at initial treatment ≤4 82 (27)
  CRP ≥8 mg/dL 166 (55)
  Thrombocytes ≤300 × 109/L 35 (12)
  ALT ≥80 IU/L 102 (34)
*Follow-up 4 weeks after onset of disease: N = 175.
†Follow-up 1 year after onset of disease: N = 177.
ALT indicates alanine aminotransferase.
TABLE 5. KD Cases Refractory to IVIG (n = 47/301): Numbers at High Risk for Being 









Relative Risk:  
High- vs.  
Low-risk Cases  












20 (31) 2.74 (1.65–4.56) 0.43 0.83 0.31 0.89 2.53 (1.60–3.77)
Kobayashi >3
n = 99
25 (25) 2.32 (1.38–3.90) 0.53 0.71 0.25 0.89 1.83 (1.31–2.54)
Sano
n = 28
13 (46) 3.73 (2.25–6.19) 0.28 0.94 0.46 0.88 4.67 (2.39–9.19)
Egami
n = 85
23 (27) 2.44 (1.46–4.07) 0.49 0.76 0.27 0.89 2.04 (1.39–2.88)
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Egami score in a population-based study.21 The English study assess-
ing the Kobyashi score for prediction of CAA in Caucasian children 
was based on small numbers (n = 20) and confined for CAA in the 
acute phase only. Loomba et al23 evaluated the Egami score vis-à-vis 
predicting IVIG resistance in KD among different ethnicities in a Mid-
west US population. Although they did not find a clinically meaning-
ful difference among the different ethnic groups, their cohort included 
just 9 children of Asian origin. Among the studies discovered, only the 
US study by Sleeper at al9 may be seen as comparable with ours with 
respect to assessment of all 3 scores in their prediction of IVIG resist-
ance and CAA (5 weeks after the acute phase of illness). Here, only the 
Kobayashi score seemed to significantly predict a high coronary artery 
Z score (P < 0.05). The association, however, was weak, showing a 
Spearman correlation coefficient of just 0.29.
STRENGTH AND LIMITATIONS
Our study is the first European study to evaluate all 3 estab-
lished Japanese risk scores in relation to a cohort of primarily Cauca-
sian children. It is also the first to provide data on the utility of these 
scores in predicting persistence of aneurysm after standard therapy 
up to 1 year after acute KD. Originally, the 3 Japanese scores were 
designed to detect resistance to IVIG. However, the most important 
impact of KD on long-term morbidity is the persistence of CAA. To 
our knowledge, to date, the association between high-risk cases as 
identified by the Japanese scores and persistent aneurysm up to 1 year 
after the acute illness has not been evaluated. In our population, the 
rates of CAA were 13% after 4 weeks and 6% after 1 year. This is in 
accordance with CAA rates reported after IVIG introduction in other 
studies.24,25 Because reporting physicians did not report coronary 
artery diameters for all patients, we had to rely on the validity of their 
diagnosis. For a subsample of 15 of 22 cases with CAA at 4 weeks, we 
were able to validate the physicians’ diagnosis of CAA since specific 
coronary artery dimensions were reported. We used the Z score equa-
tion proposed by Dallaire et al.14 In all 15 cases, the Z score was >2.5.
Because of lack of statistical power, our study did not allow 
for a meaningful assessment of the prognostic validity of these 
scores in relation to aneurysm after 4 weeks and 12 months. This 
most likely explains our failure to identify an association between 
being refractory and CAA after 12 months. Because our study 
originally was designed to assess the incidence of KD in Germany, 
statistical power calculations regarding the predictive value of dif-
ferent scores in identifying CAA had not been performed.
We conducted a number of sensitivity analyses: Among the 
301 cases in the main analysis, we reran the score test statistics 
only for those with complete data on all parameters. This yielded 
results similar to those in the main analysis (Table, Supplemen-
tal Digital Content 1, http://links.lww.com/INF/C969). To assess 
external validity with respect to the excluded children, we ran the 
score analyses for all children combined (Tables, Supplemental 
Digital Content 3–5, http://links.lww.com/INF/C971; http://links.
lww.com/INF/C972; http://links.lww.com/INF/C973). This showed 
nearly identical results. We additionally compared clinical charac-
teristics in excluded children vis-à-vis those included in the main 
analysis. These data show that exclusion of cases given steroids or 
cases for whom there was lacking information on steroid adminis-
tration, did not account for lack of external validity by confining 
the main analysis to KD cases at a lower risk (Table, Supplemental 
Digital Content 6, http://links.lww.com/INF/C974).
CLINICAL IMPLICATIONS OF THIS STUDY
A recent meta-analysis confirmed the effectiveness of corticos-
teroids in treating high-risk children.26,27 The challenge, however, is to 
identify children at high risk for KD in non-Japanese children. This is 
again outlined in the recent AHA’s scientific statement from the year 
2017.11 Adjunctive administration of corticosteroid was only recom-
mended if high-risk patients can be identified.11 Our in-depth assess-
ment of the 3 major Japanese scores, plus an additional data-driven 
score, did not indicate a reliable tool for predicting failure to respond 
to IVIG in primarily Caucasian (ie, non-Japanese) children. Because 
valid scores to identify high-risk KD children in Caucasian children 
are unavailable, supplementing IVIG with steroids for all children can 
be supported—as suggested by a recent Cochrane review28—at least 
until those who do not need this therapy escalation can be identified.
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